5Fonarow G C,Abraham WT,Albert N M,et al.Influence of Beta -Blocker Continuation or Withdrawal on Outcomes in Patients Hospitalized With Heart Failure:Findings From the OPTIMIZE-HF Program.J Am Coll Cardiol,2008,52 (3):190.
6Bergh C H,AnderssonB,Dahlstr(o)mU,et al.Intravenous levosimendan vs.dobutamine in acute decompensated heart failure patients on bets -blockers.Eur J Heart Fail 2010,12 (4):404.
7Silva-Cardoso J,Ferreira J,Oliveira-SoaresA,et al.Effectivness and safety of levosimendan in clinical practice.Rev Port Cardiol,2009,28(2):143.
8Yancy C W,Krum H,Massie B M.,et al.Safety and Efficacy of Outpatient Nesiritide in Patients With Advanced Heart Failure:Results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION Ⅱ) Trial.Circ Heart Fall,2008,1 (1):9.
9Udelson J E,Orlandi C,OuyangJ,et al.Acute Hemodynamic Effects of Tolvaptan,a Vasopressin V2 Receptor Blocker,in Patients With Symptomatic Heart Failure and Systolic Dysfunction:An International,Multicenter,Randomized,Placebo-Controlled Trial.J Am Coll Cardiol,2008,52 (19):1540.
10Blair J E,Zannad F,Konstam M A,et al.Continental Differences in Clinical Characteristics,Management,and Outcomes in Patients Hospitalized With Worsening Heart Failure:Results From the EVEREST (Efficacy of Vasopressin Antagonism in Hear Failure:Outcome Study with Tolvaptan) Program.J Am Coll Cardiol 2008,52 (20):1640.
